Current Report Filing (8-k)
04 June 2021 - 8:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
June 4, 2021
PHARMACYTE BIOTECH, INC.
(Exact Name of Registrant as Specified in its Charter)
Nevada
|
333-68008
|
62-1772151
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
23046 Avenida de la Carlota, Suite 600
Laguna Hills, CA
|
92653
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
|
|
Registrant's telephone number, including area code:
(917) 595-2850
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[_] Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
|
|
|
|
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [_]
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Item 8.01 Other Events.
On May 6, 2021, PharmaCyte
Biotech, Inc. (“PharmaCyte”) filed a Current Report on Form 8-K to provide information related to PharmaCyte’s Annual
Meeting of Stockholders and included as an exhibit a Notice of Annual Meeting of Stockholders and Proxy Statement. PharmaCyte now provides
a Supplement to the Proxy Statement as Exhibit 99.1 herein.
In addition, attached as Exhibit
99.2 is Amendment No.3 to PharmaCyte’s Bylaws.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
Dated: June 4, 2021
|
PHARMACYTE BIOTECH, INC.
|
|
|
|
By:
|
/s/ Kenneth L. Waggoner
|
|
|
Kenneth L. Waggoner
Chief Executive Officer, President and General Counsel
|